Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors

This publication has 38 references indexed in Scilit:

• Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults☆
  Vaccine, 2006
• Review on flavivirus vaccine development: Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26–27 April 2004, Bangkok, Thailand
  Vaccine, 2005
• Dengue: defining protective versus pathologic immunity
  Journal of Clinical Investigation, 2004
• Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children
  The Pediatric Infectious Disease Journal, 2004
• PHASE I TRIAL OF 16 FORMULATIONS OF A TETRAVALENT LIVE-ATTENUATED DENGUE VACCINE
  The American Journal of Tropical Medicine and Hygiene, 2003
• The future of dengue vaccines
  The Lancet, 2002
• Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.
  The American Journal of Tropical Medicine and Hygiene, 2002
• Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century
  Trends in Microbiology, 2002
• Dengue: an update
  The Lancet Infectious Diseases, 2002
• Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers
  Vaccine, 2001